🇺🇸 FDA
Pipeline program

MEPOLIZUMAB

NL83176.042.23

Approved small_molecule active

Quick answer

MEPOLIZUMAB for Eosinophilic Granulomatosis with Polyangiitis (eGPA) is a Approved program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Eosinophilic Granulomatosis with Polyangiitis (eGPA)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials